Gilead Sciences Net Income 2006-2021 | GILD

Gilead Sciences annual/quarterly net income history and growth rate from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Gilead Sciences net income for the quarter ending September 30, 2021 was $2.592B, a 620% increase year-over-year.
  • Gilead Sciences net income for the twelve months ending September 30, 2021 was $7.394B, a 483.12% increase year-over-year.
  • Gilead Sciences annual net income for 2020 was $0.123B, a 97.72% decline from 2019.
  • Gilead Sciences annual net income for 2019 was $5.386B, a 1.26% decline from 2018.
  • Gilead Sciences annual net income for 2018 was $5.455B, a 17.87% increase from 2017.
Gilead Sciences Annual Net Income
(Millions of US $)
2020 $123
2019 $5,386
2018 $5,455
2017 $4,628
2016 $13,501
2015 $18,108
2014 $12,101
2013 $3,075
2012 $2,592
2011 $2,804
2010 $2,901
2009 $2,636
2008 $1,979
2007 $1,585
2006 $-1,190
2005 $814
Gilead Sciences Quarterly Net Income
(Millions of US $)
2021-09-30 $2,592
2021-06-30 $1,522
2021-03-31 $1,729
2020-12-31 $1,551
2020-09-30 $360
2020-06-30 $-3,339
2020-03-31 $1,551
2019-12-31 $2,696
2019-09-30 $-1,165
2019-06-30 $1,880
2019-03-31 $1,975
2018-12-31 $3
2018-09-30 $2,097
2018-06-30 $1,817
2018-03-31 $1,538
2017-12-31 $-3,865
2017-09-30 $2,718
2017-06-30 $3,073
2017-03-31 $2,702
2016-12-31 $3,108
2016-09-30 $3,330
2016-06-30 $3,497
2016-03-31 $3,566
2015-12-31 $4,683
2015-09-30 $4,600
2015-06-30 $4,492
2015-03-31 $4,333
2014-12-31 $3,487
2014-09-30 $2,731
2014-06-30 $3,656
2014-03-31 $2,227
2013-12-31 $792
2013-09-30 $789
2013-06-30 $773
2013-03-31 $722
2012-12-31 $763
2012-09-30 $676
2012-06-30 $712
2012-03-31 $442
2011-12-31 $665
2011-09-30 $741
2011-06-30 $746
2011-03-31 $651
2010-12-31 $629
2010-09-30 $705
2010-06-30 $712
2010-03-31 $855
2009-12-31 $802
2009-09-30 $673
2009-06-30 $571
2009-03-31 $589
2008-12-31 $560
2008-09-30 $496
2008-06-30 $435
2008-03-31 $488
2007-12-31 $371
2007-09-30 $398
2007-06-30 $408
2007-03-31 $407
2006-12-31 $-1,666
2006-09-30 $-52
2006-06-30 $265
2006-03-31 $263
2005-12-31 $282
2005-09-30 $179
2005-06-30 $196
2005-03-31 $157
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $85.938B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81